Fig. 3: Dual inhibition of tankyrase and PD-1 confers synergistic anti-tumor efficacy in mouse melanoma.
a B16-F10 tumor (s.c.) end volume upon anti-PD-1/G007-LK treatment (−83% when compared to control) in C57BL/6 N mice treated from day 10 through 21. Control diet (n = 10), G007-LK diet (n = 10), anti-PD-1 (n = 11), and anti-PD-1/G007-LK (n = 8). Mann-Whitney rank sum tests are indicated by †(P < 0.05) and ‡(P < 0.01). For a, b Mean values are indicated by grey lines. Absence of depicted statistical comparisons indicates lack of statistical significance. b Clone M-3Z1 tumor (s.c.) end volume reduction upon anti-PD-1/G007-LK treatment (−53% when compared to control) in DBA/2 N mice treated from day 8–18. Control diet (n = 8), G007-LK diet (n = 8), anti-PD-1 (n = 11), and anti-PD-1/G007-LK (n = 10). Two-tailed t-test is indicated by *(P < 0.05). c Kaplan-Meier plot showing survival of B16-F10-recipient (s.c.) C57BL/6 N mice treated with control diet (n = 19, blue) or anti-PD-1/G007-LK (n = 16, black) from day 10 to 38. Difference between the two graphs: One-tailed log rank (Mantel-Cox) test, P = 0.087, hazard ratio = 1.75, 95% CI: 0.78–3.93. d Representative images from H&E (left and middle panels) and F4/80 and Hoechst-stained (in green and blue, respectively, right panels) tumors from control (n = 5, upper panels) and tumor implant sites of anti-PD-1/G007-LK-treated surviving mice (n = 2, lower panels). Macrophages laden with melanin are highlighted with arrows. Scale bars: H&E = 100 µm (original magnification × 100) and H&E higher magnification and F4/80 Hoechst = 50 µm (original magnification × 400).
